← Eichor
Study identifier: NCT07638345 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions

Condition: Type 1 Diabetes · T1D · Obesity & Overweight  ·  Sponsor: Adhera Health, Inc.

PhaseNA
Planned participants280
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with overweight/obesity and chronic conditions, including type 1 diabetes (T1D) and asthma. The intervention combines personalized educational content, wearable-device monitoring, psychometric assessments, and explainable artificial intelligence (AI) to improve mental well-being, quality of life, and adherence to healthy lifestyle behaviors. A total of 280 families will participate in a 3-month intervention with remote monitoring and follow-up assessments.

This description comes directly from the study's public registry record.

Talk to the study team

Luis Fernández Luque, PhD  ·  +1 (831) 345-5357  ·  luis@adherahealth.com

Always discuss trial participation with your own doctor first.

Locations (1)

Adhera Health (Virtual Participation)Seville, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07638345